inTEST (INTT) Competitors

$18.74 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$18.77 +0.04 (+0.19%)

As of 05/22/2026 07:32 PM Eastern

INTT vs. TRNS, FEIM, CTKB, LAB, and NAUT

Should you buy inTEST stock or one of its competitors? MarketBeat compares inTEST with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with inTEST include Transcat (TRNS), Frequency Electronics (FEIM), Cytek Biosciences (CTKB), Standard BioTools (LAB), and Nautilus Biotechnology (NAUT). These companies are all part of the "measuring and control equipment" industry.

How does inTEST compare to Transcat?

Transcat (NASDAQ:TRNS) and inTEST (NYSE:INTT) are both small-cap computer and technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

98.3% of Transcat shares are held by institutional investors. Comparatively, 63.2% of inTEST shares are held by institutional investors. 2.8% of Transcat shares are held by company insiders. Comparatively, 5.2% of inTEST shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Transcat had 1 more articles in the media than inTEST. MarketBeat recorded 1 mentions for Transcat and 0 mentions for inTEST. inTEST's average media sentiment score of 1.00 beat Transcat's score of 0.00 indicating that inTEST is being referred to more favorably in the news media.

Company	Overall Sentiment
Transcat	Neutral
inTEST	Positive

Transcat has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, inTEST has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market.

Transcat has higher revenue and earnings than inTEST. Transcat is trading at a lower price-to-earnings ratio than inTEST, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Transcat	$278.42M	2.45	$14.52M	$0.85	85.91
inTEST	$121.07M	1.94	$9.34M	$0.04	468.50

Transcat presently has a consensus target price of $105.33, indicating a potential upside of 44.25%. inTEST has a consensus target price of $19.00, indicating a potential upside of 1.39%. Given Transcat's higher probable upside, research analysts plainly believe Transcat is more favorable than inTEST.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Transcat	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
inTEST	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Transcat has a net margin of 2.47% compared to inTEST's net margin of 2.33%. Transcat's return on equity of 6.15% beat inTEST's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Transcat	2.47%	6.15%	4.15%
inTEST	2.33%	5.31%	3.42%

Summary

Transcat beats inTEST on 12 of the 16 factors compared between the two stocks.

How does inTEST compare to Frequency Electronics?

Frequency Electronics (NASDAQ:FEIM) and inTEST (NYSE:INTT) are both small-cap computer and technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Frequency Electronics has a net margin of 10.78% compared to inTEST's net margin of 2.33%. Frequency Electronics' return on equity of 12.69% beat inTEST's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Frequency Electronics	10.78%	12.69%	7.84%
inTEST	2.33%	5.31%	3.42%

Frequency Electronics currently has a consensus price target of $43.67, suggesting a potential downside of 35.79%. inTEST has a consensus price target of $19.00, suggesting a potential upside of 1.39%. Given inTEST's stronger consensus rating and higher probable upside, analysts plainly believe inTEST is more favorable than Frequency Electronics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Frequency Electronics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
inTEST	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

In the previous week, Frequency Electronics had 3 more articles in the media than inTEST. MarketBeat recorded 3 mentions for Frequency Electronics and 0 mentions for inTEST. inTEST's average media sentiment score of 1.00 beat Frequency Electronics' score of 0.10 indicating that inTEST is being referred to more favorably in the news media.

Company	Overall Sentiment
Frequency Electronics	Neutral
inTEST	Positive

58.6% of Frequency Electronics shares are owned by institutional investors. Comparatively, 63.2% of inTEST shares are owned by institutional investors. 28.0% of Frequency Electronics shares are owned by company insiders. Comparatively, 5.2% of inTEST shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Frequency Electronics has higher earnings, but lower revenue than inTEST. Frequency Electronics is trading at a lower price-to-earnings ratio than inTEST, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Frequency Electronics	$69.81M	9.59	$23.69M	$0.75	90.68
inTEST	$121.07M	1.94	$9.34M	$0.04	468.50

Frequency Electronics has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, inTEST has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market.

Summary

Frequency Electronics beats inTEST on 9 of the 15 factors compared between the two stocks.

How does inTEST compare to Cytek Biosciences?

Cytek Biosciences (NASDAQ:CTKB) and inTEST (NYSE:INTT) are both small-cap measuring and control equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Cytek Biosciences currently has a consensus price target of $5.69, suggesting a potential upside of 41.83%. inTEST has a consensus price target of $19.00, suggesting a potential upside of 1.39%. Given Cytek Biosciences' higher probable upside, analysts plainly believe Cytek Biosciences is more favorable than inTEST.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
inTEST	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

inTEST has a net margin of 2.33% compared to Cytek Biosciences' net margin of -36.25%. inTEST's return on equity of 5.31% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-36.25%	-10.07%	-7.56%
inTEST	2.33%	5.31%	3.42%

69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 63.2% of inTEST shares are owned by institutional investors. 10.4% of Cytek Biosciences shares are owned by company insiders. Comparatively, 5.2% of inTEST shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

inTEST has lower revenue, but higher earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than inTEST, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	2.57	-$66.54M	-$0.57	N/A
inTEST	$121.07M	1.94	$9.34M	$0.04	468.50

In the previous week, Cytek Biosciences had 1 more articles in the media than inTEST. MarketBeat recorded 1 mentions for Cytek Biosciences and 0 mentions for inTEST. inTEST's average media sentiment score of 1.00 beat Cytek Biosciences' score of 0.00 indicating that inTEST is being referred to more favorably in the news media.

Company	Overall Sentiment
Cytek Biosciences	Neutral
inTEST	Positive

Cytek Biosciences has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, inTEST has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market.

Summary

inTEST beats Cytek Biosciences on 10 of the 17 factors compared between the two stocks.

How does inTEST compare to Standard BioTools?

inTEST (NYSE:INTT) and Standard BioTools (NASDAQ:LAB) are both small-cap measuring and control equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

63.2% of inTEST shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 5.2% of inTEST shares are held by insiders. Comparatively, 23.2% of Standard BioTools shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Standard BioTools has a net margin of 73.46% compared to inTEST's net margin of 2.33%. inTEST's return on equity of 5.31% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
inTEST	2.33%	5.31%	3.42%
Standard BioTools	73.46%	-8.18%	-6.43%

inTEST presently has a consensus price target of $19.00, indicating a potential upside of 1.39%. Standard BioTools has a consensus price target of $1.35, indicating a potential upside of 31.07%. Given Standard BioTools' higher probable upside, analysts clearly believe Standard BioTools is more favorable than inTEST.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
inTEST	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Standard BioTools had 1 more articles in the media than inTEST. MarketBeat recorded 1 mentions for Standard BioTools and 0 mentions for inTEST. inTEST's average media sentiment score of 1.00 beat Standard BioTools' score of 0.95 indicating that inTEST is being referred to more favorably in the media.

Company	Overall Sentiment
inTEST	Positive
Standard BioTools	Positive

inTEST has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market.

inTEST has higher revenue and earnings than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than inTEST, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
inTEST	$121.07M	1.94	$9.34M	$0.04	468.50
Standard BioTools	$85.33M	4.71	-$74.90M	$0.20	5.15

Summary

inTEST beats Standard BioTools on 11 of the 17 factors compared between the two stocks.

How does inTEST compare to Nautilus Biotechnology?

Nautilus Biotechnology (NASDAQ:NAUT) and inTEST (NYSE:INTT) are both small-cap measuring and control equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

Nautilus Biotechnology has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market. Comparatively, inTEST has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market.

inTEST has a net margin of 2.33% compared to Nautilus Biotechnology's net margin of 0.00%. inTEST's return on equity of 5.31% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-35.04%	-29.16%
inTEST	2.33%	5.31%	3.42%

50.7% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 63.2% of inTEST shares are owned by institutional investors. 41.1% of Nautilus Biotechnology shares are owned by company insiders. Comparatively, 5.2% of inTEST shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, inTEST's average media sentiment score of 1.00 beat Nautilus Biotechnology's score of 0.00 indicating that inTEST is being referred to more favorably in the news media.

Company	Overall Sentiment
Nautilus Biotechnology	Neutral
inTEST	Positive

inTEST has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than inTEST, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A
inTEST	$121.07M	1.94	$9.34M	$0.04	468.50

Nautilus Biotechnology presently has a consensus target price of $4.00, indicating a potential upside of 57.48%. inTEST has a consensus target price of $19.00, indicating a potential upside of 1.39%. Given Nautilus Biotechnology's higher possible upside, equities analysts plainly believe Nautilus Biotechnology is more favorable than inTEST.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
inTEST	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Summary

inTEST beats Nautilus Biotechnology on 12 of the 14 factors compared between the two stocks.

Get inTEST News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INTT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INTT vs. The Competition

Export

Metric	inTEST	Instruments to measure electricity Industry	Computer Sector	NYSE Exchange
Market Cap	$235.47M	$235.47M	$39.37B	$23.20B
Dividend Yield	N/A	N/A	3.20%	4.10%
P/E Ratio	81.48	81.48	170.34	30.65
Price / Sales	1.94	1.94	628.44	24.50
Price / Cash	5.75	5.75	48.72	25.12
Price / Book	2.37	2.37	10.53	4.74
Net Income	$9.34M	$9.34M	$1.07B	$1.07B
7 Day Performance	7.09%	7.09%	3.77%	2.36%
1 Month Performance	2.07%	2.07%	6.27%	1.58%
1 Year Performance	211.30%	211.30%	169.73%	28.42%

inTEST Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INTT inTEST	1.8103 of 5 stars	$18.74 flat	$19.00 +1.4%	+211.3%	$235.47M	$121.07M	81.48	320	Positive News Gap Down High Trading Volume
TRNS Transcat	2.4817 of 5 stars	$69.64 -10.4%	$105.33 +51.3%	-20.0%	$725.21M	$319.69M	81.93	1,245	Upcoming Earnings
FEIM Frequency Electronics	1.5421 of 5 stars	$57.95 +0.3%	$43.67 -24.6%	+256.6%	$568.57M	$67.82M	77.27	200	Gap Down
CTKB Cytek Biosciences	1.7524 of 5 stars	$3.57 +0.6%	$5.69 +59.3%	+65.7%	$458.46M	$201.49M	N/A	500
LAB Standard BioTools	3.0617 of 5 stars	$1.00 +0.8%	$1.35 +35.4%	+11.8%	$386.11M	$85.33M	4.99	620

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:INTT) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

inTEST (INTT) Competitors

INTT vs. TRNS, FEIM, CTKB, LAB, and NAUT

How does inTEST compare to Transcat?

Summary

How does inTEST compare to Frequency Electronics?

Summary

How does inTEST compare to Cytek Biosciences?

Summary

How does inTEST compare to Standard BioTools?

Summary

How does inTEST compare to Nautilus Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INTT vs. The Competition

inTEST Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

inTEST (INTT) Competitors

INTT vs. TRNS, FEIM, CTKB, LAB, and NAUT

How does inTEST compare to Transcat?

Do insiders & institutionals believe in TRNS or INTT?

Does the media prefer TRNS or INTT?

Which has more volatility & risk, TRNS or INTT?

Which has preferable valuation and earnings, TRNS or INTT?

Do analysts rate TRNS or INTT?

Is TRNS or INTT more profitable?

Summary

How does inTEST compare to Frequency Electronics?

Is FEIM or INTT more profitable?

Do analysts rate FEIM or INTT?

Does the media favor FEIM or INTT?

Do insiders and institutionals hold more shares of FEIM or INTT?

Which has better valuation and earnings, FEIM or INTT?

Which has more volatility and risk, FEIM or INTT?

Summary

How does inTEST compare to Cytek Biosciences?

Do analysts rate CTKB or INTT?

Is CTKB or INTT more profitable?

Do insiders and institutionals hold more shares of CTKB or INTT?

Which has better valuation and earnings, CTKB or INTT?

Does the media favor CTKB or INTT?

Which has more volatility and risk, CTKB or INTT?

Summary

How does inTEST compare to Standard BioTools?

Do institutionals and insiders hold more shares of INTT or LAB?

Is INTT or LAB more profitable?

Do analysts rate INTT or LAB?

Does the media prefer INTT or LAB?

Which has more volatility & risk, INTT or LAB?

Which has better earnings and valuation, INTT or LAB?

Summary

How does inTEST compare to Nautilus Biotechnology?

Which has more risk & volatility, NAUT or INTT?

Is NAUT or INTT more profitable?

Do insiders and institutionals believe in NAUT or INTT?

Does the media prefer NAUT or INTT?

Which has preferable valuation & earnings, NAUT or INTT?

Do analysts prefer NAUT or INTT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INTT vs. The Competition

inTEST Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools